Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Patent metadata

Field	Value
Publication number	US-10940152-B2
Application number	US-202016846503-A
Country	US
Kind code	B2
Filing date	Apr 13, 2020
Priority date	Oct 6, 2014
Publication date	Mar 9, 2021
Grant date	Mar 9, 2021

Abstract

Provided herein are Aminopurine Compounds having the following structures:

wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

First claim

What is claimed is:

1. A method for treating melanoma, comprising administering to a patient having melanoma an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt, tautomer, stereoisomer or enantiomer thereof,
wherein:
R 1 is substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
R 2 is H or substituted or unsubstituted C 1-3 alkyl;
R 3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substituents independently selected from substituted or unsubstituted C 1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C 1-3 alkyl;
wherein when an alkyl group is substituted, it is substituted with a substituent selected from the group consisting of chloro; iodo; bromo; fluoro; alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; acyl; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aryloxyamine, aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH) 2 ; and O(alkyl)aminocarbonyl;
wherein when a group other than an alkyl group is substituted, it is substituted with a substituent selected from the group consisting of chloro; iodo; bromo; fluoro; alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; acyl; ester; urea; urethane; oxime; hydroxylamine; alkoxyamine; aryloxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxo; B(OH) 2 , O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non-fused polycyclic, or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic; monocyclic or fused or non-fused polycyclic aryl or heteroaryl; aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclylalkoxy; and
provided that the compound is not
4-[2-[(1-methyl ethyl)amino]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-9-yl]-cis-cyclohexanecarboxamide, or
4-[8-[(2,4-difluorophenyl)amino]-2-[(trans-4-hydroxycyclohexyl)amino]-9H-purin-9-yl]-cis-cyclohexanecarboxamide,
wherein said compound of formula (I) is administered to said patient in an amount of about 1 mg/day to about 1400 mg/day.

2. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in an amount of about 10 mg/day to about 1400 mg/day, about 100 mg/day to about 1400 mg/day, about 400 mg/day to about 1400 mg/day, about 600 mg/day to about 1400 mg/day, about 750 mg/day to about 1400 mg/day or about 750 mg/day to about 1350 mg/day.

3. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in a unit dosage formulation that comprises between about 1 mg and 200 mg, about 35 mg and about 1400 mg, about 125 mg and about 1400 mg, about 250 mg and about 1400 mg, about 500 mg and about 1400 mg or about 750 mg and about 1350 mg of said compound of formula (I).

4. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in a unit dosage formulation that comprises 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 900 mg, 1000 mg, 1150, 1350 or 1400 mg of said compound of formula (I).

5. The method of claim 1 , wherein said compound of formula (I) is administered to said patient once, twice, three, four or more times daily.

6. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in an amount of about 750 mg/day, about 900 mg/day, about 1150 mg/day or about 1350 mg/day.

7. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in an amount of about 750 mg/day.

8. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in an amount of about 900 mg/day.

9. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in an amount of about 1150 mg/day.

10. The method of claim 1 , wherein said compound of formula (I) is administered to said patient in an amount of about 1350 mg/day.

11. The method of claim 1 , wherein R 1 is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydro-thiopyrandioxide, piperidyl, oxepanyl, or oxaspiroheptyl, optionally substituted with one or more substituents independently selected from F, OH, SO 2 CH 3 , SO 2 -tosyl, C(═O)CH 3 , C(═O)OCH 3 , C(═O)O-tert-butyl, C(═O)O-isopropyl, C(═O)NHCH 3 , C(═O)NH-phenyl, methyl, ethyl, isopropyl, CH 2 OH, phenyl, pyridyl, or benzyl.

12. The method of claim 1 , wherein R 2 is CH 3 .

13. The method of claim 1 , wherein R 3 is 2,4,6-trihalogen substituted phenyl.

14. The method of claim 1 , wherein the compound is (1s,4s)-4-(8-(3-chlorophenylamino)-2-(isopropylamino)-9H-purin-9-yl)cyclohexanecarboxamide.

15. The method of claim 1 , wherein the compound is (1R,4s)-4-(8-(2,4-dichloro-6-fluorophenylamino)-2-((S)-1-hydroxypropan-2-ylamino)-9H-purin-9-yl)cyclohexanecarboxamide.

16. The method of claim 1 , wherein the compound is (1R,4s)-4-(8-(2,4-dichloro-6-fluorophenyl amino)-2-((S)-1-hydroxypropan-2-yl amino)-9H-purin-9-yl)-1-methylcyclohexanecarboxamide.

17. The method of claim 1 , wherein the compound is (1R,4s)-4-(8-(2,6-dichloro-4-cyanophenylamino)-2-((S)-1-hydroxypropan-2-ylamino)-9H-purin-9-yl)cyclohexanecarboxamide.

18. The method of claim 1 , wherein the compound is (1s,4s)-4-(2-(cyclobutylamino)-8-(2,6-dichloro-4-cyanophenylamino)-9H-purin-9-yl)cyclohexanecarboxamide.

19. The method of claim 1 , wherein the compound is (1s,4s)-4-(2-(cyclobutylamino)-8-(2,6-dichloro-4-cyanophenylamino)-9H-purin-9-yl)-1-methylcyclohexanecarboxamide.

20. The method of claim 1 , wherein the compound is (1s,4s)-4-(2-(3,3-difluorocyclobutylamino)-8-(2,4,6-trifluorophenylamino)-9H-purin-9-yl)-1-methylcyclohexanecarboxamide.

21. The method of claim 1 , wherein the compound is (1s,4s)-4-(2-(cyclopentylamino)-8-(2,6-dichloro-4-cyanophenylamino)-9H-purin-9-yl)cyclohexanecarboxamide.

22. The method of claim 1 , wherein the compound is (1S,4s)-4-(8-(2,6-dichloro-4-fluorophenylamino)-2-((R)-3,3-difluorocyclopentylamino)-9H-purin-9-yl)cyclohexanecarboxamide.

23. The method of claim 1 , wherein the compound is (1R,4s)-4-(2-(((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide.

24. The method of claim 1 , wherein the compound is (1R,4s)-4-(8-(2,4-dichloro-6-fluorophenyl amino)-2-((1S,3R)-3-hydroxycyclohexylamino)-9H-purin-9-yl)-1-methylcyclohexanecarboxamide.

25. The method of claim 1 , wherein the compound is (1S,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide.

26. The meth

Assignees

• Signal Pharm Llc

Inventors

• Alexander Matthew
• Bahmanyar Sogole
• Boylan John Frederick
• Hansen Joshua
• Huang Dehua
• Hubbard Robert
• Jeffy Brandon
• Leisten Jim
• Moghaddam Mehran
• Raheja Raj K
• Raymon Heather
• Schwarz Kimberly
• Sloss Marianne
• Torres Eduardo
• Tran Tam Minh
• Xu Shuichan
• Zhao Jingjing

Classifications

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/52 Primary

  Purines, e.g. adenine · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D473/32 Primary

  Nitrogen atom · CPC title

• C07D239/50

  Three nitrogen atoms · CPC title